{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:18:27Z","timestamp":1761315507512,"version":"build-2065373602"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00292-025-01472-4","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T14:13:23Z","timestamp":1758204803000},"page":"400-412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatitisdiagnostik","Hepatitis diagnostics"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4857-1561","authenticated-orcid":false,"given":"Beate K.","family":"Straub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Labenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta","family":"Drebber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"issue":"Suppl 1","key":"1472_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/liv.12409","volume":"34","author":"C Trepo","year":"2014","unstructured":"Trepo\u00a0C (2014) A brief history of hepatitis milestones. Liver Int 34(Suppl 1):29\u201337","journal-title":"Liver Int"},{"issue":"10381","key":"1472_CR2","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","volume":"401","author":"WJ Jeng","year":"2023","unstructured":"Jeng\u00a0WJ, Papatheodoridis\u00a0GV, Lok\u00a0ASF (2023) Hepatitis\u00a0B. Lancet 401(10381):1039\u20131052","journal-title":"Lancet"},{"issue":"26","key":"1472_CR3","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.3748\/wjg.v27.i26.4182","volume":"27","author":"P Veronese","year":"2021","unstructured":"Veronese\u00a0P, Dodi\u00a0I, Esposito\u00a0S, Indolfi\u00a0G (2021) Prevention of vertical transmission of hepatitis\u00a0B virus infection. World J Gastroenterol 27(26):4182\u20134193","journal-title":"World J Gastroenterol"},{"issue":"5","key":"1472_CR4","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/microorganisms11051140","volume":"11","author":"D di Filippo Villa","year":"2023","unstructured":"di Filippo Villa\u00a0D, Navas\u00a0MC (2023) Vertical transmission of hepatitis\u00a0B virus\u2014an update. Microorganisms 11(5):1140","journal-title":"Microorganisms"},{"issue":"6","key":"1472_CR5","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/hep.1840190629","volume":"19","author":"VJ Desmet","year":"1994","unstructured":"Desmet\u00a0VJ, Gerber\u00a0M, Hoofnagle\u00a0JH et\u00a0al (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19(6):1513\u20131520","journal-title":"Hepatology"},{"key":"1472_CR6","doi-asserted-by":"crossref","unstructured":"Ishak K, Baptista A, Bianchi L et\u00a0al (1995) Histological grading and staging of chronic hepatitis. J\u00a0Hepatol (22):696\u2013699","DOI":"10.1016\/0168-8278(95)80226-6"},{"issue":"2","key":"1472_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa\u00a0P, Poynard\u00a0T (1996) An algorithm for the grading of activity in chronic hepatitis\u00a0C. The METAVIR Cooperative Study Group. Hepatology 24(2):289\u2013293","journal-title":"Hepatology"},{"key":"1472_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00292-007-0963-1","volume":"29","author":"T Longerich","year":"2008","unstructured":"Longerich\u00a0T, Flechtenmacher\u00a0C, Schirmacher\u00a0P (2008) Mass und Zahl in der Hepatopathologie: Diagnostisch und klinisch relevante Graduierungen bei nichttumor\u00f6sen Lebererkrankungen. Pathologe 29:15\u201326","journal-title":"Pathologe"},{"key":"1472_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1055\/a-1498-2512","volume":"59","author":"M Cornberg","year":"2021","unstructured":"Cornberg\u00a0M, Sandmann\u00a0L, Protzer\u00a0U et\u00a0al (2021) S3-Leitlinie der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion \u2013 (AWMF-Register-Nr. 021-11). Z\u00a0Gastroenterol 59:691\u2013776","journal-title":"Z Gastroenterol"},{"key":"1472_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.humpath.2019.10.003","volume":"96","author":"D Lenggenhager","year":"2020","unstructured":"Lenggenhager\u00a0D, Weber\u00a0A (2020) Clinicopathologic features and pathologic diagnosis of hepatitis\u00a0E. Hum Pathol 96:34\u201338","journal-title":"Hum Pathol"},{"key":"1472_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41379-020-0593-1","volume":"34","author":"D Lenggenhager","year":"2021","unstructured":"Lenggenhager\u00a0D, Pawel\u00a0S, Honcharova-Biletska\u00a0H et\u00a0al (2021) The histologic presentation of hepatitis\u00a0E reflects patients\u2019 immune status and pre-existing liver condition. Mod Pathol 34:233\u2013248","journal-title":"Mod Pathol"},{"key":"1472_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/modpathol.2014.147","volume":"28","author":"U Protzer","year":"2015","unstructured":"Protzer\u00a0U, B\u00f6hm\u00a0F, Longerich\u00a0T et\u00a0al (2015) Molecular detection of hepatitis\u00a0E virus (HEV) in liver biopsies after liver transplantation. Mod Pathol 28:523\u2013532","journal-title":"Mod Pathol"},{"key":"1472_CR13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jhep.2017.04.002","volume":"67","author":"D Lenggenhager","year":"2017","unstructured":"Lenggenhager\u00a0D, Gouttenoire\u00a0J, Malehmir\u00a0M et\u00a0al (2017) Visualization of hepatitis\u00a0E virus RNA and proteins in the human liver. J\u00a0Hepatol 67:471\u2013479","journal-title":"J Hepatol"},{"key":"1472_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00292-022-01167-0","volume":"44","author":"M W\u00fchrl","year":"2023","unstructured":"W\u00fchrl\u00a0M, Ringelhan\u00a0M, Ehmer\u00a0U et\u00a0al (2023) (Seltene) infekti\u00f6se Hepatitiden als wichtige Differenzialdiagnose der unklaren Hepatopathie. Pathologie 44:53\u201362","journal-title":"Pathologie"},{"key":"1472_CR15","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00292-020-00807-7","volume":"41","author":"HP Fischer","year":"2020","unstructured":"Fischer\u00a0HP, Goltz\u00a0D (2020) Autoimmune Lebererkrankungen. Pathologe 41:444\u2013456","journal-title":"Pathologe"},{"key":"1472_CR16","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/liv.15217","volume":"42","author":"AW Lohse","year":"2022","unstructured":"Lohse\u00a0AW, Sebode\u00a0M, Bhathal\u00a0PS et\u00a0al (2022) Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group: results of a\u00a0workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology. Liver Int 42:1058\u20131069","journal-title":"Liver Int"},{"key":"1472_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes\u00a0EM, Zeniya\u00a0M, Czaja\u00a0AJ et\u00a0al (2008) International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48:169\u2013176","journal-title":"Hepatology"},{"issue":"5","key":"1472_CR18","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez\u00a0F, Berg\u00a0PA, Bianchi\u00a0FB et\u00a0al (1999) International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J\u00a0Hepatol 31(5):929\u2013938","journal-title":"J Hepatol"},{"key":"1472_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1001\/archinte.1965.03860140008003","volume":"115","author":"H Popper","year":"1965","unstructured":"Popper\u00a0H, Rubin\u00a0E, Cardiol\u00a0D, Schaffner\u00a0F, Paronetto\u00a0F (1965) Drug-induced liver disease: a\u00a0penalty for progress. Arch Intern Med 115:128\u2013136","journal-title":"Arch Intern Med"},{"key":"1472_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00292-020-00811-x","volume":"41","author":"K Apel","year":"2020","unstructured":"Apel\u00a0K, P\u00fctz\u00a0K, Tolkach\u00a0Y, Canbay\u00a0A, Drebber\u00a0U (2020) Drug-Induced Liver Injury \u2013 Stellenwert der Pathologie. Pathologe 41:457\u2013470","journal-title":"Pathologe"},{"key":"1472_CR21","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/j.transproceed.2022.04.028","volume":"54","author":"J Pohl","year":"2022","unstructured":"Pohl\u00a0J, Bischoff\u00a0P, Oellinger\u00a0R et\u00a0al (2022) Liver transplantation for Metamizole induced acute liver failure. Transplant Proc 54:1854\u20131858","journal-title":"Transplant Proc"},{"key":"1472_CR22","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1111\/liv.14985","volume":"41","author":"M Reike-Kunze","year":"2021","unstructured":"Reike-Kunze\u00a0M, Zenouzi\u00a0R, Hartel\u00a0J et\u00a0al (2021) Drug-induced liver injury at a\u00a0tertiary care centre in Germany: model for end-stage liver disease is the best predictor of outcome. Liver Int 41:2383\u20132395","journal-title":"Liver Int"},{"key":"1472_CR23","first-page":"1169","volume":"14","author":"R Teschke","year":"2018","unstructured":"Teschke\u00a0R (2018) Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method. Expert Opin Drug Metab Toxicol 14:1169\u20131187","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1472_CR24","unstructured":"LiverTox Website. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/"},{"key":"1472_CR25","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s00292-018-0519-6","volume":"39","author":"BK Straub","year":"2018","unstructured":"Straub\u00a0BK, Ridder\u00a0DA, Schad\u00a0A, Loquai\u00a0C, Schattenberg\u00a0JM (2018) Leberschaden durch Therapie mit Immun-Checkpoint-Inhibitoren: Beispiel einer immunvermittelten Medikamentennebenwirkung. Pathologe 39:556\u2013562","journal-title":"Pathologe"},{"key":"1472_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade\u00a0RJ, Chalasani\u00a0N, Bj\u00f6rnsson\u00a0ES et\u00a0al (2019) Drug-induced liver injury. Nat Rev Dis Primers 5:58","journal-title":"Nat Rev Dis Primers"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-025-01472-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-025-01472-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-025-01472-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:13:13Z","timestamp":1761315193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-025-01472-4"}},"subtitle":["Abgrenzung viraler Hepatitiden von anderen Ursachen erh\u00f6hter Transaminasen","Differential diagnosis of viral hepatitis from other causes of elevated transaminases"],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1472"],"URL":"https:\/\/doi.org\/10.1007\/s00292-025-01472-4","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"type":"print","value":"2731-7188"},{"type":"electronic","value":"2731-7196"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"B.\u00a0Straub:\n                      A.\u00a0Finanzielle Interessen: Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: med update, Bayer Healthcare, Astra Zeneca, Bristol Myers Squibb, Boehringer Ingelheim, Deutsche Leberstiftung.\u00a0\u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00e4.: IMPP (Erstellung von Pr\u00fcfungsfragen).\u00a0\u2013 Ehemann angestellt bei BioNTech, Mainz und h\u00e4lt Aktien von BioNTech.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: berufliche T\u00e4tigkeit im Institut f\u00fcr Pathologie der Unimedizin Mainz (W2-Professorin f\u00fcr Gastrointestinale Pathologie, Gesch\u00e4ftsf\u00fchrende Ober\u00e4rztin). | Mitgliedschaften: In Berufsverb\u00e4nden (DGP, IAP, BDP) sowie bei DGVS, Deutsche Leberstiftung, DGZ, u.\u202fa.\u202fm.\n                      A.\u00a0Weber:\n                      A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderungen (Projektfinanzierung) durch: Swiss National Research Foundation (SNF); Uniscientia Foundation; UZH Cancer Research Center, CRC Funding Program; Swiss Cancer Research Foundation; Hartmann M\u00fcller Stiftung.\u00a0\u2013 Referentenhonorar f\u00fcr HepaHour durch Gilead.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Professor f\u00fcr Molekulare Pathologie; Universit\u00e4t Z\u00fcrich; Stellvertretender Institutsdirektor und leitender Arzt, Universit\u00e4tsspital Z\u00fcrich | Council Member SASL | Mitgliedschaften: SGPAth, DGP.\n                      U.\u00a0Drebber:\n                      A.\u00a0Finanzielle Interessen: U.\u00a0Drebber gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Ober\u00e4rztin Institut f\u00fcr Pathologie der Uniklinik K\u00f6ln.\n                      C.\u00a0Labenz:\n                      A.\u00a0Finanzielle Interessen: Forschungsunterst\u00fctzung (\u201eunrestricted grant\u201c) von Merz Therapeutics und Norgine.\u00a0\u2013 Referentent\u00e4tigkeit: Gilead, Norgine, Merz Therapeutics, Alfasigma, Intercept\/Advanz, Ipsen, Boehringer Ingelheim, Abbvie, Falk Foundation e.\u202fV.; Reisekostenunterst\u00fctzung: Merz Therapeutics, Gilead, Intercept.\u00a0\u2013 Beratung: Boehringer Ingelheim, Ipsen, Alfasigma, Norgine, Ewimed.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: leitender Oberarzt, I.\u00a0Medizinische Klinik, Universit\u00e4tsmedizin Mainz | Mitgliedschaften: DGVS, GASL, GARPS, EASL, AASLD, ISHEN.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}